This excerpt is adapted from The Essential Guide to CBD by the Editors of Reader’s Digest and Project CBD.

Leading researchers at U.S. National Institutes of Health (NIH) recognize the importance of the endocannabinoid system as a crucial fulcrum of health. This is emphasized in a 2013 report by NIH scientists Pal Pacher and George Kunos, who maintain that “modulating endocannabinoid system activity may have therapeutic potential in almost all diseases affecting humans.”

Much depends on how the two cannabinoid receptor subtypes – CB1 and CB2 – function. In both the liver and kidneys (and other) internal organs, the CB1and CB2 receptors have a yin-yang type of relationship. When the CB1 receptor is overstimulated and there’s not enough CB2 receptor signaling, or vice versa, various diseases follow.

Chronic liver disease is a major public health problem affecting hundreds of millions of people throughout the world. Fatty liver, kidney disease, diabetes, and other diet-related metabolic disorders are expressions of overactive CB1 receptor signaling and inadequate CB2 receptor stimulation. CBD fine-tunes the endocannabinoid system by turning down the CB1 dimmer switch while mimicking and augmenting CB2 activity.

Read the full article at